Bone mineral density among elderly patients with chronic obstructive pulmonary disease patients in India

Jyothi Hattiholi, Gajanan S. Gaude

Departments of Pulmonary Medicine, Karnataka Lingayat Education University's Jawaharlal Nehru Medical College, Belgaum, Karnataka, India

ABSTRACT

Background: Osteoporosis is one of the major extra-pulmonary manifestations of chronic obstructive pulmonary disease (COPD), which limits the physical activity. The present study was undertaken to study the bone mineral density (BMD) and osteoporosis in the elderly COPD patients. Materials and Methods: This was a cross-sectional study carried out among elderly COPD patients. After a detailed clinical history spirometry was done to stage the severity of COPD. DEXA scan of the lumbar spine was performed using bone densitometer to determine osteoporosis. Statistical analysis was based on Chi-square test. Risk factors were identified by univariate and multivariate logistic regression analysis. Results: A total of 70 elderly COPD patients were included. Forty-six patients (65.7%) had osteoporosis and 13 (18.6%) had osteopenia. Majority of the osteoporosis patients had stage III or stage IV COPD disease (77.2%). As the severity grade of COPD increased, the risk of osteoporosis also increased. Also, with the increasing severity of COPD, BMD decreased. Patients with lower body mass index (BMI) had higher prevalence of osteoporosis (45.7%). Using multivariate regression analysis, stage IV COPD, number of acute exacerbations >3 and steroid cumulative dose >1000 mg were independent risk factors for osteoporosis in elderly COPD patients. Conclusions: The prevalence of osteoporosis was 65.7%, and 18.6% had osteopenia. Stage III and IV patients had significantly lower BMI in elderly COPD patients. High clinical suspicion and early diagnosis and treatment are required in the evaluation of osteoporosis in elderly COPD patients.

Key words: Bone mineral density, osteoporosis, risk factors

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a syndrome of progressive airflow limitation caused by the abnormal inflammatory reaction of the airway and lung parenchyma. It is now considered as a systemic disease with widespread extra-pulmonary manifestations. The prevalence rates of COPD in males varied from 2.12% to 9.4% in studies conducted in north India and from 1.4% to 4.1% in south India, and the rate is projected to increase by nearly 50% by the year 2016. The most common co-morbidities responsible for the clinical manifestations are cachexia, skeletal muscle abnormalities, osteoporosis, metabolic syndrome, coronary artery disease, heart failure, pulmonary infections, cancer and pulmonary vascular disease. Osteoporosis is a systemic skeletal disease characterized by a low bone mineral density (BMD) and microarchitectural changes in bones, leading to increased bone fragility and, increased fracture risk. The prevalence of osteoporosis in COPD patients is 36% to 60%. COPD patients have a higher risk of osteoporosis as compared to healthy subjects, and the loss of bone occurs over an extended period of years. When fractures occur as a complication of osteoporosis, the quality of life is further reduced. Kado et al. reported increased mortality in elderly women with vertebral. The management of COPD patients with osteoporosis poses a clinical challenge. Therefore, early diagnosis of COPD, with preventive and therapeutic measures that could avoid or reduce the consequences of osteoporosis is imperative.

This study compared the degree of osteoporosis and bone metabolism markers among elderly patients with COPD; the factors influencing bone metabolism in these patients were determined.
MATERIALS AND METHODS

This was a cross-sectional questionnaire-based study conducted in the department of Pulmonary Medicine, KLES Dr. Prabhakar Kore Hospital and Medical Research Centre, Belgaum elderly patients with COPD, between January 2010 and December 2011. The study was approved by the Institutional Ethical Committee and all the patients gave informed consent.

All the patients diagnosed as a case of COPD, based on GOLD guidelines; were included in the study. Persons of >60 years were considered as elderly group as per WHO definition of this group. 7 Bronchogenic carcinoma, untreated thyroid dysfunction, rheumatic diseases, diseases affecting bone or calcium homeostasis, primary or secondary hyperparathyroidism, Cushing’s syndrome, established osteoporosis and patients taking treatment with bone active agents and oral corticosteroids.

After a detailed demographic and clinical history, a post-bronchodilator spirometry was performed using RMS Helios 702 Spirometer (Recorders and Medicare Systems Pvt., Ltd, MEDSPIROR, India) in all patients and FVC and FEV1 were expressed as a percentage of predicted. Staging of COPD was according to GOLD criteria. 6 Peripheral blood was collected in the morning under fasting conditions, and the plasma concentrations of calcium, phosphate, total protein, albumin, BUN, creatinine, alkaline phosphatase, and urinary concentration of calcium, phosphate and creatinine were measured by routine assays. Bone mineral content (grams) and BMD (grams per centimeter squared) were measured with dual-energy X-ray absorptiometry using Lunar DPX densitometer DEXA Scan (Dual Energy X-Ray Absorptiometry) (GE Healthcare Lu andir prodiy advanc, scanner serial no. PA + 302343, software version-ENCORE 2008 version 12.2, Germany). Regions of interest that were assessed included femur and lumbar spine (L2-L4). Lumbar BMD was also expressed as a Z-score and T-score. The Z-score is a SD from the weight-adjusted average BMD for each age. A patient’s BMD was given as a T-score, which is derived by comparing it to an average score for a healthy 30-year-old of the same sex and race. The difference between the “normal young” score and the patient’s score is referred to as a standard deviation (SD). Using DEXA scan, osteoporosis was defined by a T-score of ≤−2.5, osteopenia as T-score between −1 and −2.5, and normal BMD-T score >−1. To analyze the risk factors for osteoporosis in the elderly COPD patients, we divided groups into osteoporosis and no osteoporosis (osteopenia and normal BMD combined), because only patients with osteoporosis need to be treated pharmacologically. Body mass index (BMI) was defined as underweight (<18.5 kg/m²), normal (18.5–24.9 kg/m²), overweight (≥25–29.9 kg/m²) and obese (≥30 kg/m²).

RESULTS

A total of 70 patients were included in the study. There were 45 male patients (64.3%) and 25 female patients (35.7%). The baseline patient characteristics are shown in Table 1. A total of 46 patients had osteoporosis (65.7%), 13 patients (18.6%) had osteopenia, while the rest 11 patients (15.7%) had normal bone densitometry. Mean age of the male patients was 69.6 ± 5.7 years and that of female patients was 67.4 ± 4.3 years. Nearly half of the patients (45.7%) were underweight (BMI <18.5). More than two-thirds of

| Table 1: Baseline characteristics of the patients | Men (n=45) | Women (n=25) | Total (n=70) |
|---|---|---|---|
| Age, years | 69.6±5.7 | 67.4±4.3 | 69.2±5.3 |
| FEV₁ %, Predicted | 43.3±17.7 | 40.7±17.3 | 42.7±16.9 |
| Stage I | 6.6 | 4.0 | 5.7 |
| Stage II | 15.6 | 20.0 | 17.1 |
| Stage III | 42.2 | 40.0 | 41.5 |
| Stage IV | 35.6 | 36.0 | 35.7 |
| Smoking | | | |
| Current smoker | 22.2 | — | 14.3 |
| Ex-smoker, % | 64.4 | — | 41.4 |
| Pack years | 15.9 | — | 15.9 |
| BMI, kg/m² | 22.74±4.4 | 20.35±4.5 | 21.44±4.7 |
| Low, % | 44.4 | 48.8 | 45.7 |
| Normal, % | 24.5 | 32.0 | 27.1 |
| High, % | 22.2 | 22.0 | 18.6 |
| Obese, % | 8.9 | 8.0 | 8.6 |
| DEXA Scan, Hip and LS | | | |
| BMD, g/cm² | 1.112±0.114 | 1.078±0.125 | 1.117±0.114 |
| T-Score | −2.6±1.5 | −2.71±1.9 | −2.61±1.8 |
| Normal BMD, % | 78.8 | 72.0 | 75.7 |
| Osteopenia, % | 17.8 | 20.0 | 18.6 |
| Osteoporosis, % | 64.4 | 68.0 | 65.7 |
| Duration of illness (%) | | | |
| <5 years | 11.1 | 16.0 | 12.8 |
| 5–10 years | 66.7 | 56.0 | 62.8 |
| >10 years | 22.2 | 28.0 | 24.4 |
| Inhaled Steroids, % | 32.6 | 33.4 | 32.5 |
| Complications, if any (n) | 3 | 1 | 5 |
| Deaths (n) | 2 | 1 | 3 |

Results are presented as means±standard deviation, unless otherwise indicated, LS – Lumbar spine, BMI – Body mass index, BMD – Bone mineral density.
the male patients were smokers, while none of the women patients were smokers.

Majority of the elderly patients who had osteoporosis had stage III and stage IV COPD disease (77.2%). Stage I and stage II COPD disease had less prevalence of osteoporosis. It was observed that, as the severity grade of COPD increased, the risk of osteoporosis had also increased. Almost 85% of the patients who had suffered ≥3 exacerbations in the past 3 years had osteoporosis, while all the patients with >5 exacerbations in the past 3 years had osteoporosis.

The BMD of the hip and lumbar area of the spine were significantly lowered in elderly patients with COPD [Table 2]. BMD showed a significant difference (P < 0.0001) among the different stages of COPD [Table 3]. As the severity of stage of COPD increased, the BMD decreased.

The various risk factors for osteoporosis in COPD such as BMI, smoking and use of corticosteroids in elderly COPD patients were analyzed. It was observed that underweight patients had higher prevalence of osteoporosis (45.7%) as compared to overweight patients. Obese individuals had protective effect against development of osteoporosis (8.6%). But, this association was not statistically significant (P < 0.073). In this study, all female patients were non-smokers. Smoking was found to have no association with COPD. Comparing only among smokers, osteoporosis was observed to be more prevalent in those with >10 pack years smoking history (24.6%) as compared to the patients having pack year history of ≤10 (11.8%) (P < 0.3).

Most of the patients with COPD are prescribed steroids during any exacerbations, and the use of steroids may increase with the number of exacerbations and hospitalizations. All the patients were categorized as those not on any steroids, those who used only inhaled steroids, those who used <1000 mg of steroids (cumulative dose; equivalent of prednisolone) and those who used >1000 mg (cumulative dose; equivalent of prednisolone). Osteoporosis was observed to be high in those using >1000 mg (cumulative dose; prednisolone) (P < 0.0001). It was also observed that the risk of developing osteoporosis in COPD patients using inhaled corticosteroids was almost the same as those not using inhaled corticosteroids (3.9% versus 6.8% respectively).

The various factors were analyzed to evaluate the role of each factor in the predisposition for osteoporosis in elderly COPD patients. By performing simple univariate analysis, it was observed that the risk factors for osteoporosis in COPD were female sex, number of exacerbations, BMI and severity of COPD. After using multivariate logistic regression analysis, the significant risk factors observed for the development of osteoporosis in elderly COPD were the number of acute exacerbation of COPD ≥3, COPD stage IV disease and the use of steroids >1000 mg (cumulative dose; equivalent of prednisolone) [Table 4].

**DISCUSSION**

Osteoporosis is more prevalent among COPD patients than among healthy subjects. Thus, it is important to recognize the risk factors and strategies to manage osteoporosis in elderly COPD patients in order to avoid osteoporotic fractures, since it deteriorates the quality of life and prognosis. In this study, we compared the degree of BMD among COPD patients in the elderly patients and determined the factors that influence bone metabolism in these patients. This study has clearly shown that, in elderly patients with COPD, the lumbar and hip BMD was much lower.

In the present study, the prevalence of osteoporosis in elderly COPD patients was 65.7% and that of osteopenia was 18.6%. Various studies done in different parts of the world showed prevalence of osteoporosis to be 9%-69% in COPD patients versus 0%-13% in healthy individuals. Katsura and Kida have observed the prevalence of osteoporosis in patients with COPD to be 50%, and this was significantly higher than that of bronchial asthma. The prevalence of osteoporosis was reported to be 24% among postmenopausal women in Japan, and the prevalence of osteoporosis in women with COPD was almost two-fold higher than that in the general population. Among various studies done, study by Verboom et al, and TORCH trial were landmark studies. They found prevalence of osteoporosis to be 21% and 65% and that of osteopenia to be 41% and 65%, respectively. An Indian study recently done among 37 patients showed a prevalence of osteoporosis to be 21.6% and that of osteopenia to be 27%. But, this study had used calcaneal USG for the diagnosis of osteoporosis, which is not a standard test. We used DEXA scan for the diagnosis of osteoporosis, which is considered as a gold standard test, and

**Table 2: Bone densitometry data**

| Bone data   | Men       | Women      | Total       |
|-------------|-----------|------------|-------------|
| Total body BMD, gm/cm² | 1.12±0.18  | 1.14±0.12 | 1.13±0.121 |
| Spine BMD gm/cm²    | 0.9±0.06   | 0.86±0.15  | 0.9±0.12   |
| Z score              | -0.3±0.27  | -0.2±0.29  | -0.3±0.27  |
| T score              | -2.6±1.5   | -2.7±1.9   | -2.6±1.8   |

| COPD severity | Normal (BMD) (gm/cm²) | Osteopenia (BMD) (gm/cm²) | Osteoporosis (BMD) (gm/cm²) | Mean±SD   |
|---------------|-----------------------|----------------------------|-----------------------------|------------|
| Stage I       | 1.23±0.83             | 1.17±0.12                  | 0.89±0.53                   | 1.14±0.20  |
| Stage II      | 1.14±0.83             | 1.11±0.12                  | 0.84±0.53                   | 1.17±0.23  |
| Stage III     | 1.33±0.83             | 0.97±0.12                  | 0.73±0.53                   | 0.85±0.22  |
| Stage IV      | 0                     | 0.93±0.12                  | 0.73±0.53                   | 0.73±0.14  |
| Mean±SD       | 1.21±0.12±0.83        | 1.01±0.12                  | 0.74±0.12                   | 0.74±0.12  |

COPD – Chronic obstructive pulmonary disease
In the present study, higher prevalence of osteoporosis was observed in female COPD patients ($P < 0.005$), as females are at increased risk for development of osteoporosis. A recent Japanese study\textsuperscript{11} observed two-fold higher prevalence of osteoporosis in female COPD patients. In a meta-analysis, it was observed that the prevalence of osteoporosis varied from 9% to 69%, and that there was higher proportion of women patients with COPD. There is a definite relation between the severity of COPD disease and the risk of development of osteoporosis. In the present study, majority of patients who had osteoporosis had grade IV COPD (93.7%). Also, BMD reduced as the severity of the disease progressed ($P < 0.004$). In a study by Stevenson et al.,\textsuperscript{13} it was observed that there was increased incidence of osteopenia and osteoporosis with advancing COPD stage. They observed that 68% had either low bone mass (osteopenia or osteoporosis) or a previously undiagnosed vertebral fracture, with 25% of the included patients having a vertebral fracture. Consistent with the above studies, another study by de Vries et al.,\textsuperscript{14} observed that the risk of osteoporotic fracture increased in patients with COPD (OR 1.61; 95% CI 1.52-1.71). It was also observed that patients with more severe airway obstruction in COPD had increased risks of osteoporosis and bone fractures as compared with patients without a history of obstructive airway disease. Three cross-sectional observational studies described an independent association between osteoporosis with poor pulmonary function (FEV\textsubscript{1} predicted). In these studies, BMD decreased approximately 0.02 g/cm\textsuperscript{2} for every 1 L/s decrease in FEV\textsubscript{1} and had a 2.4 increased risk of osteoporosis. COPD patients are associated with a 1.2- to 1.3-fold higher risk of fractures.\textsuperscript{15} Graat-Verboom et al.,\textsuperscript{1} observed that, as severity of COPD increased, the prevalence of osteoporosis also increased. In another study, similar findings of higher prevalence of osteoporosis in stage III and stage IV COPD disease as compared to stage I and stage II COPD were observed.\textsuperscript{16} The TORCH study\textsuperscript{16} demonstrated a higher prevalence of osteoporosis and osteopenia at baseline in COPD patients, but there was no association between FEV\textsubscript{1} impairment and BMD when adjusted by age and gender.\textsuperscript{17}

Smoking is a well-known cause of COPD, and it has also been found to be an independent risk factor for osteoporosis in both men and women.\textsuperscript{17,18} Slemenda et al.,\textsuperscript{19} reported that lumbar spine BMD was 12% lower in smokers who have smoked 20 pack-years as compared to non-smokers. Both vertebral fractures and hip fractures were found to be higher in smokers. The pathophysiologic mechanism for the lower bone mass and increased fracture risk in smokers is unclear. A study\textsuperscript{20} showed evidence of decreased calcium absorption in the gastrointestinal
Corticosteroids, commonly prescribed to patients with COPD or asthma, are known to reduce bone formation and increased bone resorption. As the number of exacerbations of COPD increases, the cumulative dose of parental steroids also increases. The dose of steroids during exacerbation of COPD is much higher, which may contribute to the higher incidence of reduced BMD. Also, the number of exacerbations is affected by prolonged immobilization. In the present study, majority of the patients with COPD were prescribed steroids during exacerbations, and the use of steroids increases with a number of exacerbations and hospitalizations. Osteoporosis was observed to be high in those using >1000 mg (cumulative dose, prednisolone) \( (P < 0.0001) \). Normal bone metabolism is a result of the equilibrium between bone formation by osteoblasts and bone resorption by osteoclasts. The mechanism of bone loss induced by glucocorticoids is two-fold, with decreased bone formation and increased bone resorption.\(^{28}\) Similar findings have been observed by Bhattacharya et al.,\(^{12}\) in Indian COPD patients.

The risk of developing osteoporosis in COPD patients using inhaled corticosteroids was observed to be almost the same as those not using inhaled corticosteroids in the present study (3.9% versus 6.8% respectively). Similar results were observed in a study by Canalis et al.\(^{29}\) They studied patients with more severe COPD and found that they had higher risks of fracture and that these risks were comparable between users and nonusers of inhaled corticosteroids. TORCH study\(^{10}\) investigated the long-term effects of therapy with inhaled steroids on BMD and bone fractures in patients with moderate-to-severe COPD. No significant differences were observed between placebo and inhaled steroids group. The incidence of fractures also was low and was similar for all treatments (5.1% to 6.3%). Whether ICS therapy produces adequate blood levels that can adversely affect BMD is not certain, but even a small effect over an extended period of time may produce serious side effects.\(^{29}\) Also, a Cochrane review\(^{30}\) of randomised clinical trials found no evidence of effect of inhaled-corticosteroid exposure on BMD in COPD patients. Thus, this trend is consistent with the current hypothesis that underlying disease severity is important in the aetiology of reduced BMD in COPD patients rather than using inhaled corticosteroids.\(^{31,32}\)

We hypothesized that corticosteroids, smoking, physical inactivity, low body weight and/or malnutrition can explain the lower BMD and higher rates of osteoporosis in elderly patients with COPD. Elderly patients with moderate to severe COPD have advanced nature of the disease, which predisposes them to osteoporosis by virtue of being elderly or chronically disabled and having chronic systemic inflammation. Low-grade systemic inflammation persists even in non-smoking subjects with chronic airflow limitation, suggesting that smoking cessation does not
eliminate ongoing inflammation and that inflammation is not due to tobacco alone.\textsuperscript{32} Another potential mechanism could be due to hypercapnia, which has been associated with increased bone resorption.\textsuperscript{34} Dimai et al.\textsuperscript{35} showed that lower arterial pH and higher arterial carbon dioxide levels were correlated with lower BMD in COPD patients. Finally, hormonal levels may be another mechanism. Hormone replacement therapy and increased circulating estrogen levels had a protective effect on pulmonary function in pre- and postmenopausal women.\textsuperscript{36} Further studies to examine whether inflammation, hypercapnia or sex hormones mediates the relationship between COPD and BMD are needed.

In summary, it is now established that osteoporosis in COPD is multifactorial. It is evident from the present study that COPD is now increasingly being recognized as an inflammatory condition of the lung, and, over the past decade, it has been recognized for its systemic inflammation and having extra-pulmonary manifestations. Patients with COPD are often treated with oral or parenteral glucorticoids during exacerbations. Such oral or parenteral glucorticoid therapy along with various other risk factors clearly increases the risk for the development of osteoporosis.

This study has certain limitations. First, data on physical activity and exact smoking status were limited. Second, there were no data on the loss of fat-free mass. Loss of fat-free mass has been associated with reduced BMD and more severe COPD and might be a more concise marker of severity of COPD as compared with BMI. Third, there was no control group. This becomes difficult when the test is costly, making it difficult for a normal person to affirm it. Lastly, among patients who used inhaled steroids, about 40\% were using oral corticosteroids during exacerbations. Therefore, it may be difficult in this patient group to separate the effects of oral and inhaled corticosteroids.

In conclusion, the results of our study demonstrated that osteoporosis is common among elderly COPD patients even if these patients did not receive systemic corticosteroids. The development of osteoporosis in COPD is multi-factorial, but preventive strategies to decrease osteoporotic fractures should be added to the management of elderly patients with COPD. Hence, in an ideal set-up, all patients with COPD should be screened for osteoporosis using BMD measurements made by DEXA for the early diagnosis, and proper therapy of this condition can be advised at the earliest.

REFERENCES

1. Murray CJ, Lopez AD. Global mortality, disability and the contribution of risk factors: Global burden of disease study. Lancet 1997;349:1436-42.
2. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, \textit{et al.} Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-65.
3. Graat-Verboom L, Wouters EF, Smeen FW, van den Borne BE, Lunde R, Spruit MA. Current status of research on osteoporosis in COPD: A systematic review. Eur Respir J 2009;34:209-18.
4. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008;31:204-12.
5. Sin DD, Leung R, Gan WQ, Man SP. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: A pilot study. BMC Pulm Med 2007;7:13.
6. Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR. Vertebral fractures and mortality in older women: A prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999;159:1215-20.
7. WHO definition. Definition of an older or elderly person. Available from: http://www.who.int/healthinfo/survey/ageingdefolder/en/index.html [Last accessed on 2012 Dec 28].
8. Kanis JA. On behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level: Technical report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK; 2008.
9. Ohara T, Hirai T, Muro S, Haruna A, Terada K, Kineo D, \textit{et al.} Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest 2008;134:1244-9.
10. Orimo H, Sugioya Y, Fukunaga M, \textit{et al.} Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 1998;16:139-50.
11. Katsura H, Kida K. A comparison of bone mineral density in elderly female patients with COPD and bronchial asthma. Chest 2002;122:1949-55.
12. Bhattacharya P, Paul R, Ghosh M, Dey R, Dey R, Barooah N, \textit{et al.} Prevalence of osteoporosis and osteopenia in advanced chronic obstructive pulmonary disease patients. Lung India 2011;28:184-6.
13. Stevenson JC, Lees B, Devenport M, Cust MP, Ganger KF. Determinants of bone density in normal women: Risk factors for future osteoporosis? BMJ 1989;298:924-8.
14. de Vries F, van Staa TP, Bracke MS, Cooper C, Leufkens HG, Lammers JW. Severity of obstructive airway disease and risk of osteoporotic fracture. Eur Respir J 2005;25:879-84.
15. Mazess RB, Barden HS, Drinka PJ, Bauwens SF, Orwell ES, Bell NH. Influence of age and body weight on spine and femur bone mineral density in US white men. J Bone Miner Res 1990;5:645-52.
16. Mazess RB, Barden HS. Bone density in premenopausal women: Effects of age, dietary intake, physical activity, smoking and birth control pills. Am J Clin Nutr 1991;53:132-42.
17. Ferguson GT, Calverley PM, Anderson JA, Jenkins CR, Jones PW, Willits LR, \textit{et al.} Prevalence and progression of osteoporosis in patients with COPD: Results from the towards a revolution in COPD Health Study. Chest 2009;136:1456-65.
18. Baldock PA, Thomas GP, Hodge JM, Baker SU, Dressel U, O’Loughlin PD, \textit{et al.} Vitamin D action and regulation of bone remodeling: Suppression of osteoclastogenesis by the mature osteoblast. J Bone Miner Res 2008;21:1618-26.
19. Slemenda CW, Hui SL, Longcope C, Johnston CC Jr. Cigarette smoking, obesity, and bone mass. J Bone Miner Res 1989;4:737-41.
20. Cooper C, Bker DJ, Wickham C. Physical activity, muscle strength, and calcium intake in fracture of the proximal femur in Britain. BMJ 1988;297:1443-6.
21. Krall EA, Dawson-Hughes B. Smoking and bone loss among postmenopausal women. J Bone Miner Res 1991;6:331-8.
22. Marquis K, Debigare R, Lacase Y, LeBlanc P, Jobin J, Carrier G, \textit{et al.} Midthigh muscle cross-sectional area is a better
predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:809-13.
23. Wilson DO, Rogers RM, Wright EC, Anthonisen NR. Body weight in chronic obstructive pulmonary disease: The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. Am Rev Respir Dis 1989;139:1435-8.
24. Grey AB, Ames RW, Matthews RD, Reid IR. Bone mineral density and body composition in adult patients with cystic fibrosis. Thorax 1993;48:589-93.
25. Seeman E. The effects of tobacco and alcohol use on bone. In: Marcus R, Feldman J, Kelsey J, editors. Osteoporosis. New York: Academic Press; 1996. p. 577-97.
26. Incalzi RA, Caradonna P, Ranieri P, Basso S, Fusco L, Pagano F, et al. Correlates of osteoporosis in chronic obstructive pulmonary disease. Respir Med 2000;94:1079-84.
27. DiFrancia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;150:1453-5.
28. Manolagas SC. Role of cytokines in bone resorption. Bone 1995;17:63-75.
29. Canalis E, Mazzotti G, Giustina A, Bilezikian JP. Glucocorticoid induced osteoporosis: Pathophysiology and therapy. Osteoporos Int 2007;18:1319-28.
30. Jones A, Fay JK, Burr M, Stone M, Hood K, Roberts G. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002;1:CD003537.
31. Richy F, Bousquet J, Ehrlich GE, Meunier PJ, Israel E, Monii H, et al. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: A quantitative systematic review. Osteoporos Int 2003;14:179-90.
32. Man SF, Sin DD. Thinning bone and inhaled corticosteroid in COPD: What to do until there is definitive proof? Chest 2009;136:1448-9.
33. Crook MA, Scott DA, Stapleton JA, Palmer RM, Wilson RF, Sutherland G. Circulating concentrations of C-reactive protein and total sialic acid in tobacco smokers remain unchanged following one year of validated smoking cessation. Eur J Clin Invest 2000;30:861-5.
34. Sin DD, Man SF. Skeletal muscle weakness, reduced exercise tolerance, and COPD: Is systemic inflammation the missing link? Thorax 2006;61:1-3.
35. Dimai HP, Domej W, Leb G, Lau KH. Bone loss in patients with untreated chronic obstructive pulmonary disease is mediated by an increase in bone resorption associated with hypercapnia. J Bone Miner Res 2001;16:2132-41.
36. Carlson CL, Cushman M, Enright PL, Cauley JA, Newman AB. Cardiovascular Health Study Research Group. Hormone replacement therapy is associated with higher FEV1 in elderly women. Am J Respir Crit Care Med 2001;163:423-8.

How to cite this article: Hattiholi J, Gaude GS. Bone mineral density among elderly patients with chronic obstructive pulmonary disease patients in India. Niger Med J 2013;54:295-301.

Source of Support: Nil, Conflict of Interest: None declared.